Viking Therapeutics is a clinical-stage biopharmaceutical company developing therapies for metabolic and endocrine diseases. Its pipeline is best known for VK2735, an investigational dual GLP-1/GIP receptor agonist aimed at obesity and related metabolic conditions, along with other candidates targeting rare metabolic and endocrine disorders. The company focuses on advancing these programs through clinical development rather than marketing approved commercial products.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 0 | — | -65.6 | — |
| Q3 2025 | 0 | — | -90.8 | — |
| Q4 2025 | 0 | — | -157.7 | — |
| Q1 2026 | 0 | — | -158.3 | — |
| Q2 2026 | 0 | — | -128 | — |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Simmons First National Corporation (SFNC), Tarsus Pharmaceuticals, Inc. (TARS), Mechanics Bancorp (MCHB), IDEAYA Biosciences, Inc. (IDYA), Pulse Biosciences, Inc. (PLSE), Slide Insurance Holdings, Inc. (SLDE)